共 50 条
- [41] PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal DegradationBLOOD, 2019, 134Scarpa, MarioSingh, PrernaKapoor, ShivaniLee, Jonelle K.Niyongere, SandrineNarla, GouthamPerrotti, DaniloBaer, Maria R.
- [42] Improved Posttransplant Outcomes in Recent Years for AML Patients with FLT3-ITD and Wild-type NPM1: A Report from the EBMT Acute Leukemia Working PartyCLINICAL CANCER RESEARCH, 2023, 29 (21) : 4441 - 4448Bazarbachi, AliLabopin, MyriamGedde-Dahl, TobiasRemenyi, PeterForcade, EdouardKroeger, NicolausSocie, GerardCraddock, CharlesBourhis, Jean HenriVersluis, JurjenYakoub-Agha, IbrahimSalmenniemi, UrpuEl-Cheikh, JeanBug, GesineEsteve, JordiNagler, ArnonCiceri, FabioMohty, Mohamad
- [43] A novel Axl and Mertk dual inhibitor ONO-7475: A new therapeutic agent for the treatment of FLT3-ITD and -wild-type acute myeloid leukemia (AML) overexpressingCANCER RESEARCH, 2018, 78 (13)Tanaka, KoheiLi, CuifangHirosaki, TomomiKato, HikaruIshikawa, YoshinoriOka, MihoEgawa, HiroshiKozaki, RyoheiYoshizawa, Toshio
- [44] High-throughput Identification of FLT3 Wild-type and Mutant Kinase Substrate Preferences and Application to Design of Sensitive In Vitro Kinase Assay SubstratesMOLECULAR & CELLULAR PROTEOMICS, 2019, 18 (03) : 477 - 489Perez, MinervoBlankenhorn, JohnMurray, Kevin J.Parker, Laurie L.
- [45] CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic riskLEUKEMIA RESEARCH, 2013, 37 (11) : 1488 - 1494Park, Sang HyukChi, Hyun-SookCho, Young-UkJang, SeongsooPark, Chan-Jeoung
- [46] Potent graft-versus-leukaemia effect after reduced-intensity allogeneic stem-cell transplantation as post-remission therapy for intermediate-risk de-novo AML with FLT3-ITD genotype or wild-type (WT) NPM1 and CEBPA without FLT3-ITDBONE MARROW TRANSPLANTATION, 2012, 47 : S417 - S418Laboure, G.Vigouroux, S.Dulucq, S.Labopin, M.Lippert, E.Pigneux, A.Tabrizi, R.Leguay, T.Bouabdallah, K.Dilhuydy, M. S.Schmitt, A.Marit, G.Mahon, F. X.Milpied, N.
- [47] LAM-003, a Novel Oral Heat Shock Protein 90 Inhibitor for Treatment of Acute Myeloid Leukemia, Including Wild-Type and FMS-like Tyrosine Kinase 3 (FLT3)-Mutant DiseaseBLOOD, 2019, 134Beeharry, NeilLandrette, SeanGrotzke, JeffGayle, SophiaHernandez, MarylensHalene, StephanieYoung, Peter R.Miller, Langdon L.Xu, TianRothberg, JonathanLichenstein, Henri
- [48] Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (28) : 4339 - 4345Fischer, ThomasStone, Richard M.DeAngelo, Daniel J.Galinsky, IleneEstey, ElihuLanza, CarloFox, EdwardEhninger, GerhardFeldman, Eric J.Schiller, Gary J.Klimek, Virginia M.Nimer, Stephen D.Gilliland, D. GaryDutreix, CatherineHuntsman-Labed, AliceVirkus, JodiGiles, Francis J.
- [49] QuANTUM-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication (FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed Through Induction and Consolidation Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (ND) FLT3-ITD+ AML PatientsCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S298 - S298Perl, Alexander E.Erba, Harry P.Montesinos, PauVrhovac, RadovanPatkowska, ElzbietaKim, Hee-JeZak, PavelWang, Po-NanRohrbach, Jaime E. ConnollyChang, Ken C. N.Liu, LiKamel, Yasser MostafaImadalou, KarimaLesegretain, ArnaudCortes, JorgeSekeres, Mikkael A.Dombret, HerveAmadori, SergioWang, JianxiangSchlenk, Richard F.Levis, Mark J.
- [50] Concurrent Inhibition of Pim-1 and FLT3 Kinases in FLT3-ITD Acute Myeloid Leukemia Post-Translationally Downregulates the Anti-Apoptotic Protein Mcl-1 through Downregulation of the Mcl-1 Deubiquitinase USP9XBLOOD, 2016, 128 (22)Baldwin, Patrick R.Kapoor, ShivaniNatarajan, KarthikaTrotta, RossanaTron, AdrianaHuszar, DennisDavila, EduardoPerrotti, DaniloBaer, Maria R.